Entry Rationale
On 2026‑08‑31, the closing price of 171.42 dollars is near the recent low of 169.76 dollars, near the short-term support line, expecting a rebound and considered buying.
Ducommun Non-GAAP EPS of $1.18 beats by $0.20, revenue of $224.5M beats by $10.18M
Ducommun reported Non‑GAAP EPS of $1.18, exceeding the prior year by $0.20, and sales of $224.5M, exceeding the prior year by $10.18M, as positive catalyst.
On 2026‑08‑31, the closing price of 171.42 dollars is near the recent low of 169.76 dollars, near the short-term support line, expecting a rebound and considered buying.
If it reaches $196.8, I will execute the REPORTING-derived take-profit target, and if it drops to $161.87, I will sell at the REPORTING-derived stop-loss.
RSI(14) 68.7 (near overbought), moving average golden cross (upward trend), trading volume 0.83x the 20-day average (weak volume), recent 7-day fluctuation rate +4.4% (upward price momentum).
The prediction expected a 2.5% rise based on EPS and sales growth supported by technical indicators, but actually fell -10.6% and reached the stop-loss line. I overlooked the fact that RSI was in the overbought zone and trading volume was below average, as the price failed to rebound near the bottom, which was the main reason.
In the next trade, give greater weight to overbought signals and low trading volume, and confirm that the price is forming above a clear support level before entry. Additionally, when setting a stop-loss, leave a buffer above the recent low to account for volatility, and avoid making a buy decision solely based on news catalysts.